Immune Design

Immune Design is a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is focused on oncology and have engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells, or CTLs, to fight cancer. Its immuno-oncology product candidates are being developed in two separate approaches: one that targets specific antigens and/or epitopes; and an alternative approach that leverages the endogenous antigens found in the tumor microenvironment via intratumoral immunization. The specific antigen approach uses selected antigens that are also present in the patient’s tumor so that the immune system will be educated to recognize the tumor antigen and kill tumor cells expressing the antigen.

Type
Public
HQ
Seattle, US
Founded
2008
Size (employees)
50 (est)+22%
Immune Design was founded in 2008 and is headquartered in Seattle, US

Immune Design Office Locations

Immune Design has offices in Seattle and South San Francisco
Seattle, US (HQ)
310 1616 Eastlake Ave E
South San Francisco, US
250 601 Gateway Blvd

Immune Design Data and Metrics

Immune Design Financial Metrics

USD

Market capitalization (19-Jul-2017)

234 m

Closing share price (19-Jul-2017)

9.2
Immune Design's current market capitalization is $234 m.

Immune Design Operating Metrics

FY, 2016

Phase I Trials

1

Phase II Trials

3

Phase Preclinical

2

Patents (US)

16

Patents (foreign)

19

Immune Design Market Value History

Immune Design News and Updates

Immune Design Company Life and Culture

You may also be interested in